Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1
NCT07038915 · M.D. Anderson Cancer Center · PHASE2 · withdrawn · last registry update 2025-08-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “0 participants” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TIGIT within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-08-03Results posted on the registry: Hoffmann-La Roche, 5-Fluorouracil (5-FU) + Leucovorin (NCT03281369)
- 2026-08-03Also stopped (terminated): Hoffmann-La Roche, 5-Fluorouracil (5-FU) + Leucovorin (NCT03281369)
- 2026-08-03Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Enfortumab Vedotin (NCT03869190)
- 2026-08-03Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Enfortumab Vedotin (NCT03869190)
- 2026-07-08Results posted on the registry: M.D. Anderson Cancer Center, Nivolumab + Etigilimab (NCT05715216)
- 2026-06-18Results posted on the registry: Hoffmann-La Roche, Tiragolumab and Atezolizumab IV FDC (NCT05661578)
- 2026-06-10Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Tiragolumab (NCT06267001)
- 2026-06-10Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Tiragolumab (NCT06267001)
- 2026-06-08Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab + Pembrolizumab/Quavonlimab (NCT04895722)
- 2026-06-04Also stopped (suspended): James Cleary, MD, PhD, ZIMBERELIMAB + DOMVANALIMAB (NCT05419479)
- 2026-06-03Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Tiragolumab (NCT04513925)
- 2026-06-03Results posted on the registry: Hoffmann-La Roche, Tiragolumab + Atezolizumab (NCT04619797)
- 2026-05-12Results posted on the registry: BeiGene, Tislelizumab + Ociperlimab (NCT04746924)
- 2026-05-12Also stopped (terminated): BeiGene, Tislelizumab + Ociperlimab (NCT04746924)
- 2026-05-12Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Cobimetinib (NCT03337698)
- 2026-05-12Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Cobimetinib (NCT03337698)
- 2026-05-05Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Tiragolumab (NCT04665843)
- 2026-05-04Results posted on the registry: Mayo Clinic, Atezolizumab + Cobimetinib (NCT03554083)
- 2026-05-01Also stopped (withdrawn): MedSIR, Zimberelimab (AB122) + Domvanalimab (DOM) (NCT07134556)
- 2026-04-15Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Capecitabine (NCT05251948)
- 2026-04-15Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Capecitabine (NCT05251948)
- 2026-04-09Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Tiragolumab (NCT04540211)
- 2026-03-23Also stopped (withdrawn): Gustave Roussy, Cancer Campus, Grand Paris, Atezolizumab 1200 mg IV + Tiragolumab 600 mg IV (NCT06713798)
- 2026-03-11Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Tiragolumab (NCT04832854)
- 2026-03-11Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Tiragolumab (NCT04832854)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision